China and the US Race to Complete the Second Phase of the Corona Vaccine Clinical Trial

China and the US Race to Complete the Second Phase of the Corona Vaccine Clinical TrialChina and the US Race to Complete the Second Phase of the Corona Vaccine Clinical Trial – Chinese pharmaceutical company CanSino Biologics reports it has begun a second phase of clinical trials of one of the COVID-19 vaccines, claims the Ministry of Research and Technology in Beijing.
As for the United States, vaccine development is carried out by the National Institutes of Health and Moderna Inc. (NIH) not far behind. Volunteers who took the first phase of clinical trials last month are now preparing to receive a second dose of the experimental vaccine.

Head of the Infectious Disease Section at NIH, Dr. Anthony Fauci acknowledged, so far his side has not received a red flag in the first phase of clinical trials and hopes to be able to hold a larger clinical trial in June.

While the third vaccine candidate developed by Inovio Pharmaceuticals has begun undergoing the first phase of clinical trials last week in the United States and later in China.

Testing phase of vaccine effectiveness

If the first phase of development focuses more on safety, the second phase is carried out to collect clinical data from as many volunteers as possible, to find out the effectiveness of vaccines to immobilize the virus in the body.

Last week CanSino claimed it had gathered 500 volunteers to undergo the second phase of clinical trials. In the process scientists will test two doses of vaccine by injection

China and the US Race to Complete the Second Phase of the Corona Vaccine Clinical Trial

On Monday (13/4) CanSino reported that 273 volunteers had received vaccine injections.

Meanwhile Dr. Fauci predicts that if the corona outbreak continues to rage until the fall at the end of the year, the vaccine development process could be accelerated rather than 12 to 18 months as predicted at the beginning.

According to him in that case, COVID-19 vaccine could be available in mid or late winter, which ranges from December to March 2021

Please remember, all of that is based on the assumption that the vaccine is functioning effectively. And this is a big question mark, he said. The vaccine must be effective and safe to use.

China keeps quality

The Chinese government also sent a similar warning. Even though we are in an emergency situation, vaccine safety and efficacy standards cannot be lowered, said Wang Junzhi, a health expert in China.

The community is closely watching the vaccine development process, he added.

The World Health Organization (WHO) noted dozens of COVID-19 vaccine candidates who are undergoing an initial phase of development worldwide. The hope is that if one of the candidates is proven to fail, other candidates can also be developed later.

The vaccine developed by CanSino is rumored to be based on one of the Ebola Poker Online Medan vaccines that was manipulated to reduce the corona virus. While vaccines developed in the United States rely on corona virus DNA sequencing published by Chinese scientists in January.